Deerfield Management Company, L.P. (Series C) Lumos Pharma, Inc. Transaction History

Deerfield Management Company, L.P. (Series C)

  • $5.38 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 15, 2021
SELL
$7.36 - $11.36 $243,741 - $376,209
-33,117 Closed
0 $0
Q2 2021

Aug 16, 2021
SELL
$9.75 - $13.44 $3.32 Million - $4.57 Million
-340,000 Reduced 91.12%
33,117 $331,000
Q1 2021

May 17, 2021
SELL
$11.58 - $31.11 $6.52 Million - $17.5 Million
-563,174 Reduced 60.15%
373,117 $4.37 Million
Q3 2020

Nov 16, 2020
BUY
$13.25 - $16.5 $1,616 - $2,013
122 Added 0.01%
936,291 $12.9 Million
Q1 2020

May 15, 2020
BUY
$0.89 - $8.85 $833,190 - $8.29 Million
936,169 New
936,169 $7.96 Million

Others Institutions Holding LUMO

# of Institutions
33
Shares Held
2.2M
Call Options Held
0
Put Options Held
0
View Full List

About LUMOS PHARMA, INC.

LUMO Quotes by TradingView
  • Ticker LUMO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 8,396,070
  • Market Cap $36.4M
  • Description
  • Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare en...
More about LUMO
Track This Portfolio

Track Deerfield Management Company, L.P. (Series C) Portfolio

Follow Deerfield Management Company, L.P. (Series C) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email